MBP8298 starting phase III SPMS trial in US
Posted: Fri Jan 19, 2007 11:56 am
The more the merrier...
BioMS gets FDA approval to start Phase 3 MS trial
Jan 19, 2007 - Reuters - BioMS Medical Corp. said on Friday it has received U.S. Food and Drug Administration approval to begin a Phase 3 trial of its multiple sclerosis treatment.
The two-year trial will involve about 500 patients in 50 centers across the United States, chief executive Kevin Giese told Reuters.
Giese said the trial of its treatment for secondary progressive MS is expected to be completed by the end of 2009, with market approval expected about a year later.
"This is big for us. This makes it one of the two pivotal trials we have ongoing in secondary progressive," Giese said.
The U.S. trial complements a trial the company is conducting in Canada and Europe, which is nearing completion of enrollment.
"We have never been in the United States with an open IND (investigational new drug application) before, so getting approval for the Phase 3, and coming with data from outside of the United States is quite an accomplishment," Giese said.
"I think it is really very supportive of the good clinical data that we have had to date."
reference
BioMS gets FDA approval to start Phase 3 MS trial
Jan 19, 2007 - Reuters - BioMS Medical Corp. said on Friday it has received U.S. Food and Drug Administration approval to begin a Phase 3 trial of its multiple sclerosis treatment.
The two-year trial will involve about 500 patients in 50 centers across the United States, chief executive Kevin Giese told Reuters.
Giese said the trial of its treatment for secondary progressive MS is expected to be completed by the end of 2009, with market approval expected about a year later.
"This is big for us. This makes it one of the two pivotal trials we have ongoing in secondary progressive," Giese said.
The U.S. trial complements a trial the company is conducting in Canada and Europe, which is nearing completion of enrollment.
"We have never been in the United States with an open IND (investigational new drug application) before, so getting approval for the Phase 3, and coming with data from outside of the United States is quite an accomplishment," Giese said.
"I think it is really very supportive of the good clinical data that we have had to date."
reference